Guardant Health, Inc.
GHNASDAQHealthcare● Active
$127.58
+$1.97(+1.56%)
Market Cap$16.9B
P/E Ratio—
52W High$133.97
52W Low$40.35
Guardant Health, Inc. (GH) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
GH · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.85
Est. -$0.81 · -5.5%
Revenue
$0.30B
Est. $0.28B · +8.1%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
GH reports quarterly as a NASDAQ-listed Medical - Diagnostics & Research company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 29, 2026 | -$0.42 | — | — | — | $0.31B | — |
| ▼ Q2 FY2026 | May 7, 2026 | -$0.81 | -$0.85 | -5.5% | $0.30B | $0.28B | +8.1% |
| ▼ Q1 FY2026 | Feb 19, 2026 | -$0.77 | -$0.90 | -17.4% | $0.28B | $0.27B | +3.3% |
| ▲ Q4 FY2025 | Oct 29, 2025 | -$0.48 | -$0.39 | +18.8% | $0.27B | $0.27B | -0.9% |
| ▲ Q3 FY2025 | Jul 30, 2025 | -$0.52 | -$0.44 | +15.4% | $0.23B | $0.24B | -1.5% |
| ▲ Q2 FY2025 | Apr 30, 2025 | -$0.61 | -$0.49 | +19.7% | $0.20B | $0.21B | -3.8% |
| ▲ Q1 FY2025 | Feb 20, 2025 | -$0.75 | -$0.62 | +17.3% | $0.20B | $0.19B | +4.8% |
| ▲ Q4 FY2024 | Nov 6, 2024 | -$0.55 | -$0.45 | +18.2% | $0.19B | $0.19B | +1.3% |
Q3 FY2026
Jul 29, 2026
EPS Actual
—
EPS Est.
-$0.42
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Miss
EPS Actual
-$0.85
EPS Est.
-$0.81
EPS Surpr.
-5.5%
Revenue
$0.30B
Q1 FY2026
Feb 19, 2026Miss
EPS Actual
-$0.90
EPS Est.
-$0.77
EPS Surpr.
-17.4%
Revenue
$0.28B
Q4 FY2025
Oct 29, 2025Beat
EPS Actual
-$0.39
EPS Est.
-$0.48
EPS Surpr.
+18.8%
Revenue
$0.27B
Q3 FY2025
Jul 30, 2025Beat
EPS Actual
-$0.44
EPS Est.
-$0.52
EPS Surpr.
+15.4%
Revenue
$0.23B
Q2 FY2025
Apr 30, 2025Beat
EPS Actual
-$0.49
EPS Est.
-$0.61
EPS Surpr.
+19.7%
Revenue
$0.20B
Q1 FY2025
Feb 20, 2025Beat
EPS Actual
-$0.62
EPS Est.
-$0.75
EPS Surpr.
+17.3%
Revenue
$0.20B
Q4 FY2024
Nov 6, 2024Beat
EPS Actual
-$0.45
EPS Est.
-$0.55
EPS Surpr.
+18.2%
Revenue
$0.19B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.36 | $0.37 | $0.38 | 5 |
| Q3 FY2028 | $0.27 | $0.28 | $0.28 | 5 |
| Q2 FY2028 | $-0.02 | $-0.02 | $-0.02 | 5 |
| Q1 FY2028 | $-0.23 | $-0.23 | $-0.22 | 5 |
| Q4 FY2027 | $-0.27 | $-0.26 | $-0.25 | 4 |
| Q3 FY2027 | $-0.38 | $-0.37 | $-0.35 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.6B | $0.6B | $0.6B | 6 |
| Q3 FY2028 | $0.5B | $0.6B | $0.6B | 5 |
| Q2 FY2028 | $0.5B | $0.5B | $0.5B | 5 |
| Q1 FY2028 | $0.5B | $0.5B | $0.5B | 6 |
| Q4 FY2027 | $0.5B | $0.5B | $0.5B | 6 |
| Q3 FY2027 | $0.4B | $0.4B | $0.4B | 6 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 7, 2026 | -5.5% | $92.25 | $92.26 | +0.01% |
| ▼ Q1 FY2026 | Feb 19, 2026 | -17.4% | $107.42 | $106.38 | -0.97% |
| ▲ Q4 FY2025 | Oct 29, 2025 | +18.8% | $69.58 | $72.27 | +3.87% |
| ▲ Q3 FY2025 | Jul 30, 2025 | +15.4% | $43.32 | $45.19 | +4.32% |
| ▲ Q2 FY2025 | Apr 30, 2025 | +19.7% | $49.53 | $47.23 | -4.64% |
| ▲ Q1 FY2025 | Feb 20, 2025 | +17.3% | $49.00 | $47.40 | -3.27% |
| ▲ Q4 FY2024 | Nov 6, 2024 | +18.2% | $23.52 | $25.29 | +7.53% |
| ▲ Q3 FY2024 | Aug 7, 2024 | +15.8% | $32.16 | $33.96 | +5.60% |
Q2 FY2026+0.01%
Report Date
May 7, 2026
EPS Beat/Miss
-5.5%
Price Before
$92.25
Price After
$92.26
Q1 FY2026-0.97%
Report Date
Feb 19, 2026
EPS Beat/Miss
-17.4%
Price Before
$107.42
Price After
$106.38
Q4 FY2025+3.87%
Report Date
Oct 29, 2025
EPS Beat/Miss
+18.8%
Price Before
$69.58
Price After
$72.27
Q3 FY2025+4.32%
Report Date
Jul 30, 2025
EPS Beat/Miss
+15.4%
Price Before
$43.32
Price After
$45.19
Q2 FY2025-4.64%
Report Date
Apr 30, 2025
EPS Beat/Miss
+19.7%
Price Before
$49.53
Price After
$47.23
Q1 FY2025-3.27%
Report Date
Feb 20, 2025
EPS Beat/Miss
+17.3%
Price Before
$49.00
Price After
$47.40
Q4 FY2024+7.53%
Report Date
Nov 6, 2024
EPS Beat/Miss
+18.2%
Price Before
$23.52
Price After
$25.29
Q3 FY2024+5.60%
Report Date
Aug 7, 2024
EPS Beat/Miss
+15.8%
Price Before
$32.16
Price After
$33.96
Avg Beat Reaction+2.24%
Avg Miss Reaction-0.48%
Beat Rate6 / 8 quarters
Largest Move+7.53% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: GH ends December
Guardant Health, Inc. (GH) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.85 — missing the analyst consensus of $-0.81 by -5.5%. The next GH earnings date is expected around September 1, 2026.
Each quarter, investors track GH earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. GH revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
GH's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
GH earnings · 5 questionsGuardant Health, Inc.'s next earnings report is expected around September 1, 2026. GH typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; GH historically reports after market close (AMC).
GH earnings datewhen is GH earningsGH next earnings datewhen does GH report earningsGH earnings calendar
▸ Source: FMP · Guardant Health, Inc. SEC filings · US GAAP · Guardant Health, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026